Search - Université de Rennes Access content directly

Filter your results

33 Results
authFullName_s : Laurent Alric

Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study)

Victor De Ledinghen , Claire Laforest , Christophe Hézode , Stanislas Pol , Alain Renault et al.
Hepatology, 2017, 64 (6), pp.1130A--1130A
Journal articles hal-01487921v1

ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts

Isabelle Ollivier-Hourmand , Yohann Repesse , Pierre Nahon , Cendrine Chaffaut , Thông Dao et al.
Liver International, 2022, 42 (6), pp.1386-1400. ⟨10.1111/liv.15159⟩
Journal articles hal-03553907v1
Image document

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

Christophe Hézode , Hélène Fontaine , Céline Dorival , Fabien Zoulim , Dominique Larrey et al.
Gastroenterology, 2014, 147 (1), pp.132-142.e4. ⟨10.1053/j.gastro.2014.03.051⟩
Journal articles inserm-01057763v1

LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather

S. Pol , M. Bourlière , S. Lucier , V. de Ledinghen , F. Zoulim et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. pp.S258--S259, ⟨10.1016/S0168-8278(15)30149-5⟩
Conference papers hal-01162711v1

P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey

A. Garioud , J. -F. Cadranel , A. Pauwels , T. Thevenot , A. Louvet et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S833, 2015, ⟨10.1016/S0168-8278(15)31461-6⟩
Conference poster hal-01162774v1
Image document

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment a prospective cohort study

Fabrice Carrat , Hélène Fontaine , Céline Dorival , Mélanie Simony , Alpha Diallo et al.
The Lancet, 2019, 393 (10179), pp.1453-1464. ⟨10.1016/S0140-6736(18)32111-1⟩
Journal articles hal-02050395v1

Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort

Sepolene Brichler , Richard Layese , Valérie Bourcier , Carole Cagnot , Patrick Marcellin et al.
Hepatology, 2016, 63 (1 SUPP), pp.898A--899A
Journal articles hal-01414692v1

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

Charlotte Costentin , Richard Layese , Valérie Bourcier , Carole Cagnot , Patrick Marcellin et al.
Gastroenterology, 2018, 155 (2), pp.431-442.e10. ⟨10.1053/j.gastro.2018.04.027⟩
Journal articles hal-02648451v1
Image document

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

Anne Laurain , Sophie Metivier , Georges Haour , Dominique Larrey , Céline Dorival et al.
BMC Infectious Diseases, 2019, 19 (1), pp.300. ⟨10.1186/s12879-019-3923-5⟩
Journal articles hal-02120879v1

EFFICACY AND SAFETY OF TREATMENT WITH BULEVIRTIDE IN CHRONIC HEPATITIS DELTA: PRELIMINARY RESULTS OF THE REAL LIFE ANRS HD EP01 BULEDELTA COHORT

Fabien Zoulim , Claire Fougerou , Roulot Marullo Dominique , Sophie Metivier , Victor de Ledinghen et al.
Hepatology, 2022, 76 (Supp 1), pp.S221-S223
Journal articles hal-03922586v1
Image document

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

E. Rosenthal , C Fougerou-Leurent , A. Renault , Mp. Carrieri , F. Marcellin et al.
HIV Medicine, 2018, 19 (3), pp.227-237. ⟨10.1111/hiv.12571⟩
Journal articles hal-01740817v1
Image document

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

Isabelle Poizot-Martin , Eric Bellissant , Rodolphe Garraffo , Philippe Colson , Lionel Piroth et al.
HIV Clinical Trials, 2016, 17 (2), pp.63-71. ⟨10.1080/15284336.2015.1135553⟩
Journal articles hal-01299973v1

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs

Pierre Nahon , Richard Layese , Valérie Bourcier , Carole Cagnot , Patrick Marcellin et al.
Gastroenterology, 2018, 155 (5), pp.1436-1450.e6. ⟨10.1053/j.gastro.2018.07.015⟩
Journal articles hal-02648450v1

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)

Jean-Claude Trinchet , Valérie Bourcier , Cendrine Chaffaut , Mohand Ait Ahmed , Setty Allam et al.
Hepatology, 2015, 62 (3), pp.737-750. ⟨10.1002/hep.27743⟩
Journal articles hal-01201948v1
Image document

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

Manon Allaire , Pierre Nahon , Richard Layese , Valérie Bourcier , Carole Cagnot et al.
Hepatology, 2018, 68 (4), pp.1245-1259. ⟨10.1002/hep.30034⟩
Journal articles hal-02648452v1
Image document

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients

Stanislas Pol , Marc Bourlière , Sandy Lucier , Christophe Hézode , Céline Dorival et al.
Journal of Hepatology, 2017, 66 (1), pp.39-47. ⟨10.1016/j.jhep.2016.08.021⟩
Journal articles hal-01435007v1
Image document

Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study

Victor de Ledinghen , Claire Laforest , Christophe Hezode , Stanislas Pol , Alain Renault et al.
Infectious Diseases in Clinical Practice, 2018, 66 (7), pp.1013-1018. ⟨10.1093/cid/cix916⟩
Journal articles hal-01743768v1

Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)

Pierre Nahon , Mathilde Lescat , Richard Layese , Valérie Bourcier , Nabila Talmat et al.
Gut, 2017, 66 (2), pp.330-341. ⟨10.1136/gutjnl-2015-310275⟩
Journal articles hal-01225507v1
Image document

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)

Nathalie Ganne-Carrié , Richard Layese , Valérie Bourcier , Carole Cagnot , Patrick Marcellin et al.
Hepatology, 2016, 64 (4), pp.1136-1147. ⟨10.1002/hep.28702⟩
Journal articles hal-01381662v1

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

Marc Bourlière , Jean-Pierre Bronowicki , Victor de Ledinghen , Christophe Hézode , Fabien Zoulim et al.
The Lancet Infectious Diseases, 2015, 15 (4), pp.397-404. ⟨10.1016/S1473-3099(15)70050-2⟩
Journal articles hal-01134440v1

P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic

J. -P. Bronowicki , H. Fontaine , C. Dufour , F. Zoulim , D. Larrey et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S617--S618, 2015, ⟨10.1016/S0168-8278(15)30971-5⟩
Conference poster hal-01162777v1

LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather

H. Fontaine , C. Hezode , F. Zoulim , D. Samuel , M. Bourlière et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S278, 2015, ⟨10.1016/S0168-8278(15)30182-3⟩
Conference poster hal-01162770v1

Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort

Hélène Fontaine , Claire Fougerou-Leurent , Emmanuel Gordien , Caroline Scholtès , Sophie Métivier et al.
Journal of Hepatology, 2022, 77, pp.S72-S72
Journal articles hal-03770282v1
Image document

Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study

Laurent Lam , Hélène Fontaine , Marc Bourliere , Clovis Lusivika-Nzinga , Céline Dorival et al.
Clinics and Research in Hepatology and Gastroenterology, 2021, 45 (5), pp.101713. ⟨10.1016/j.clinre.2021.101713⟩
Journal articles hal-03224103v1
Image document

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?

Audrey Coilly , Jérôme Dumortier , Danielle Botta-Fridlund , Marianne Latournerie , Vincent Leroy et al.
PLoS ONE, 2015, 10 (9), pp.e0138091. ⟨10.1371/journal.pone.0138091⟩
Journal articles hal-01326372v1

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890

Christophe Hézode , Hélène Fontaine , Céline Dorival , Dominique Larrey , Fabien Zoulim et al.
Journal of Hepatology, 2013, 59 (3), pp.434 - 441. ⟨10.1016/j.jhep.2013.04.035⟩
Journal articles hal-01708037v1
Image document

Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?

Lucy Meunier , Mohamed Belkacemi , George Philippe Pageaux , Sylvie Radenne , Anaïs Vallet-Pichard et al.
Viruses, 2023, 15 (1), pp.137. ⟨10.3390/v15010137⟩
Journal articles hal-03980202v1

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.

Eric Lawitz , Edward Gane , Brian Pearlman , Edward Tam , Wayne Ghesquiere et al.
The Lancet, 2015, 385 (9973), pp.1075-86. ⟨10.1016/S0140-6736(14)61795-5⟩
Journal articles hal-01142117v1

Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B)

Eric Lawitz , Edward J. Gane , Brian Pearlman , Edward Tam , Wayne Ghesquiere et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Nov 2014, Boston, United States
Conference papers hal-03252092v1

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

Charlotte Costentin , Richard Layese , Valérie Bourcier , Carole Cagnot , Patrick Marcellin et al.
Gastroenterology, 2018, 155 (2), pp.431-442.e10. ⟨10.1053/j.gastro.2018.04.027⟩
Journal articles hal-04075104v1